BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iparomlimab (QL1604) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Iparomlimab (QL1604)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07026422-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07026422)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvonralima
 b Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced
  Rectal Cancer (IT-TNT)\nEstimated primary completion: 30 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0702642
 2
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007728-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07007728)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvonralima
 b Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorecta
 l Cancer Liver Metastasis\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007
 728
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291401-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07291401)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Radiotherapy Plus CAPOX
 \, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LA
 RC\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07291401
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930118-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT06930118)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: The Aim of This Study i
 s to Assess the Efficacy and Safety of Chidamide\, Regorafenib in Combinat
 ion With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colore
 ctal Cancer in Third-line Therapy and Subsequent Lines.\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/iparomlimab-ql1604#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06930118
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310069-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07310069)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Gemcitabine and Nab-Pac
 litaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder
  Cancer\nEstimated primary completion: 1 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07310069
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876154-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07876154)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvonralima
 b Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Lo
 cally Advanced Cervical Cancer\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0787615
 4
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139587-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab (QL1604): Phase na readout est. (NCT07139587)
DESCRIPTION:Iparomlimab (QL1604)\, phase na.\nStudy: The Efficacy and Safet
 y of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bou
 nd Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/G
 astroesophageal Junction Adenocarcinoma\nEstimated primary completion: Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab
 -ql1604#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07139587
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160647-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07160647)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: The Efficacy and Safety
  of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advan
 ced MSI-H/dMMR Colorectal Cancer: An Prospective\, Single-Arm Study (Neo-I
 T)\nEstimated primary completion: 30 August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07160647
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232654-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07232654)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvonralima
 b Injection Plus CCRT in LACC\nEstimated primary completion: 30 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql16
 04#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7232654
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085234-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07085234)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvorlimab 
 (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07085234
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348861-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07348861)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: A Phase II Study of Neo
 adjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvon
 ralimab in Locally Advanced Cervical Cancer\nEstimated primary completion:
  1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipar
 omlimab-ql1604#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07348861
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267078-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07267078)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Tuvonralimab and Iparom
 limab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
 \nEstimated primary completion: 25 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07267078
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878222-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT06878222)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab and Tuvonra
 limab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
 \nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06878222
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07945782-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Iparomlimab (QL1604): Phase 1/2 readout est. (NCT07945782)
DESCRIPTION:Iparomlimab (QL1604)\, phase 1/2.\nStudy: A Phase I/II Single-A
 rm\, Open-Label\, Exploratory Study Evaluating the Safety and Efficacy of 
 Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparom
 limab-Toripalimab in Borderline Resectable Pancreatic Cancer\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07945782
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595523-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07595523)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab Tolvorlimab
  as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma 
 With Microsatellite Instability/Mismatch Repair Deficiency\nEstimated prim
 ary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iparomlimab-ql1604#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07595523
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619235-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Iparomlimab (QL1604): Phase 4 readout est. (NCT07619235)
DESCRIPTION:Iparomlimab (QL1604)\, phase 4.\nStudy: A Single-arm\, Multicen
 ter Clinical Study of Iparomlimab and Toripalimab in Combination With Beva
 cizumab and Chemotherapy as First-line Treatment for Advanced Biliary Trac
 t Cancer\nEstimated primary completion: 1 July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07619235
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT06145308)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Precision Treatment of 
 Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\n
 Estimated primary completion: 10 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062055-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280725
DTEND;VALUE=DATE:20280726
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07062055)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: BITS-TO-HCC Study: HAIC
 +Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With
  PVTT and/or Oligometastases\nEstimated primary completion: 25 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070620
 55
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801287-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07801287)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvonralima
 b Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Rese
 ctable Intermediate-Stage HCC\nEstimated primary completion: 15 August 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 01287
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829874-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280920
DTEND;VALUE=DATE:20280921
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07829874)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Cryoablation Combined W
 ith QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Adv
 anced Biliary Tract Cancer.\nEstimated primary completion: 20 September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql160
 4#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 829874
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347444-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07347444)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab and Tuvoral
 eimab Injection in Combination With Bevacizumab\, Albumin-bound Paclitaxel
 \, and Carboplatin as First- or Second-line Treatment for Patients With Ad
 vanced Acral and Mucosal Melanoma\nEstimated primary completion: December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1
 604#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07347444
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649473-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07649473)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: QL1706 Combined With St
 andard Therapy for Conversion Therapy of Synchronous Liver Metastases From
  Colon Cancer: a Multicenter\, Single-arm\, Exploratory Study\nEstimated p
 rimary completion: 31 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07649473
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035808-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07035808)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: a Single Arm\, Phase II
  Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Com
 bination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Beva
 cizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Pati
 ents With Advanced Cervical Cancer .\nEstimated primary completion: 31 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlim
 ab-ql1604#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07035808
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315035-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07315035)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: QL1706-SOX vs SOX Alone
  as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07315035
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673835-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07673835)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab and Tuvonra
 limab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase 
 II）\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07673835
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514793-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07514793)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab Plus Tovori
 limab Combined With Bevacizumab and Chemotherapy as First-Line Treatment f
 or Advanced Mesothelioma\nEstimated primary completion: April 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07514793
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379398-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07379398)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab and Tuvonra
 limab Injection Combined With SBRT in Patients With Early-Stage Non-Small 
 Cell Lung Cancer\nEstimated primary completion: 30 June 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07379398
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686640-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Iparomlimab (QL1604): Phase 3 readout est. (NCT07686640)
DESCRIPTION:Iparomlimab (QL1604)\, phase 3.\nStudy: Short-Course Radiothera
 py Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/
 MSS Locally Advanced Rectal Cancer\nEstimated primary completion: 15 July 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1
 604#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07686640
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454018-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07454018)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: Iparomlimab/Tuvonralima
 b + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ova
 rian Cancer\nEstimated primary completion: 31 December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07454018
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06864013-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT06864013)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: SCRT Combined With Chem
 otherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Loc
 ally Advanced Rectal Cancer\nEstimated primary completion: 31 December 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 64013
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940478-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Iparomlimab (QL1604): Phase 2 readout est. (NCT07940478)
DESCRIPTION:Iparomlimab (QL1604)\, phase 2.\nStudy: A Single-Arm\, Explorat
 ory\, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local T
 herapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Ve
 in Tumor Thrombus\nEstimated primary completion: 1 March 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07940478
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602063-7709@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Iparomlimab (QL1604): Phase 1/2 readout est. (NCT06602063)
DESCRIPTION:Iparomlimab (QL1604)\, phase 1/2.\nStudy: Surgery for Relapsed 
 Ovarian Cancer in Precision\nEstimated primary completion: June 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-ql1604#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06602063
URL:https://assetmemo.bio/drug/iparomlimab-ql1604#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
